Protecting the peritoneal membrane: Factors beyond peritoneal dialysis solutions

Nature Reviews Nephrology

Volumn 8, Issue 9, 2012, Pages 542-550

  Pletinck, Anneleen ^a   Vanholder, Raymond ^a   Veys, Nic ^a   Van Biesen, Wim ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENFOTIAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; GELATINASE A; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXAMINE; SULODEXIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALPORT SYNDROME; CLINICAL PRACTICE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIALYSATE; GENETICS; HUMAN; PERITONEAL DIALYSIS; PERITONEAL MEMBRANE; PERITONEUM; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; UREMIA;

BICARBONATES; BIOCOMPATIBLE MATERIALS; DIALYSIS SOLUTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIMARY PREVENTION; RISK ASSESSMENT; TREATMENT OUTCOME; UREMIA;

EID: 84865492297     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.144     Document Type: Review

References (90)

1. Lameire, N., Van Biesen, W. & Vanholder, R. The role of peritoneal dialysis as first modality in an integrative approach to patients with end-stage renal disease. Perit. Dial. Int. 20 (Suppl. 2), S134-S141 (2000
2. Davies, S. J. et al. What really happens to people on long-term peritoneal dialysis? Kidney Int. 54, 2207-2217 (1998
3. Williams, J. D. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 13, 470-479 (2002
4. Wieslander, A. P. Cytotoxicity of peritoneal dialysis fluid -is it related to glucose breakdown products? Nephrol. Dial. Transplant. 11, 958-959 (1996
5. Fusshoeller, A., Baehr, J., Grabensee, B. & Plum, J. Biocompatibility of a bicarbonate/lactate-buffered PD fluid tested with a double-chamber cell culture system. Perit. Dial. Int. 25, 387-393 (2005
6. Grossin, N. et al. Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid. Perit. Dial. Int. 26, 664-670 (2006
7. Oh, E. J. et al. Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum. Am. J. Nephrol. 31, 58-67 (2010
8. Witowski, J. et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J. Am. Soc. Nephrol. 11, 729-739 (2000
9. Witowski, J. et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J. Am. Soc. Nephrol. 12, 2434-2441 (2001
10. Kim, C. D. et al. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model. Ther. Apher. Dial. 11, 56-64 (2007
11. Mortier, S., De Vriese, A. S. & Lameire, N. Recent concepts in the molecular biology of the peritoneal membrane -implications for more biocompatible dialysis solutions. Blood Purif. 21, 14-23 (2003
12. Mortier, S., Faict, D., Schalkwijk, C. G., Lameire, N. H. & De Vriese, A. S. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int. 66, 1257-1265 (2004
13. Mortier, S., Faict, D., Lameire, N. H. & De Vriese, A. S. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int. 67, 1559-1565 (2005
14. Mortier, S., Faict, D., Gericke, M., Lameire, N. & De Vriese, A. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp. Nephrol. 101, e139-e145 (2005
15. Witowski, J. & Jorres, A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit. Dial. Int. 25 (Suppl. 3), S31-S34 (2005
16. Johnson, D. W. et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J. Am. Soc. Nephrol. 23, 1097-1107 (2012
17. Sampimon, D. E., Coester, A. M., Struijk, D. G. & Krediet, R. T. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol. Dial. Transplant. 26, 291-298 (2011
18. Garcia-Lopez, E., Lindholm, B. & Davies, S. An update on peritoneal dialysis solutions. Nat. Rev. Nephrol. 8, 224-233 (2012
19. Rumpsfeld, M., McDonald, S. P., Purdie, D. M., Collins, J. & Johnson, D. W. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am. J. Kidney Dis. 43, 492-501 (2004
20. Van Biesen, W. et al. The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 1, 269-274 (2006
21. Nakamoto, H. et al. Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD. Am. J. Kidney Dis. 40, 1045-1054 (2002
22. Honda, K. et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: A quantitative study of peritoneal membrane morphology. Clin. J. Am. Soc. Nephrol. 3, 720-728 (2008
23. Stoenoiu, M. S. et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int. 62, 668-678 (2002
24. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008
25. De Vriese, A. S., Tilton, R. G., Stephan, C. C. & Lameire, N. H. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J. Am. Soc. Nephrol. 12, 1734-1741 (2001
26. Combet, S. et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J. Am. Soc. Nephrol. 12, 2146-2157 (2001
27. Vrtovsnik, F. et al. Induction of chronic kidney failure in a long-term peritoneal exposure model in the rat: Effects on functional and structural peritoneal alterations. Perit. Dial. Int. 30, 558-569 (2010
28. Kakuta, T. et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int. 68, 1326-1336 (2005
29. Osada, S. et al. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol. Dial. Transplant. 24, 3504-3512 (2009
30. De Vriese, A. S., Tilton, R. G., Mortier, S. & Lameire, N. H. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol. Dial. Transplant. 21, 2549-2555 (2006
31. Numata, M. et al. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin. Nephrol. 62, 455-460 (2004
32. Pletinck, A. et al. Salt intake induces epithelialtomesenchymal transition of the peritoneal membrane in rats. Nephrol. Dial. Transplant. 25, 1688-1696 (2010
33. Pecoits-Filho, R., Carvalho, M. J., Stenvinkel, P., Lindholm, B. & Heimburger, O. Systemic and intraperitoneal interleukin6 system during the first year of peritoneal dialysis. Perit. Dial. Int. 26, 53-63 (2006
34. Stenvinkel, P., Barany, P., Heimburger, O., Pecoits-Filho, R. & Lindholm, B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin6? Kidney Int. Suppl. 103-108 (2002
35. Sawai, A. et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol. Dial. Transplant. 26, 2322-2332 (2011
36. Oh, K. H. et al. Intra-peritoneal interleukin6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol. Dial. Transplant. 25, 1639-1646 (2010
37. Gillerot, G. et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int. 67, 2477-2487 (2005
38. Hwang, Y. H. et al. Effects of interleukin6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. Perit. Dial. Int. 29, 81-88 (2009
39. Oh, K. H. et al. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients. Nephrol. Dial. Transplant. 23, 2356-2364 (2008
40. Lee, Y. T. et al. Association between interleukin10 gene polymorphism 592 (A/C) and peritoneal transport in patients undergoing peritoneal dialysis. Nephrology (Carlton) 16, 663-671 (2011
41. Johnson, D. W. et al. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol. Dial. Transplant. 25, 1973-1979 (2010
42. Rodrigues, A. S. et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am. J. Nephrol. 27, 84-91 (2007
43. Wong, T. Y. et al. Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. Am. J. Kidney Dis. 42, 781-786 (2003
44. Zeier, M. et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int. 63, 298-305 (2003
45. Thomas, M. C. Advanced glycation end products. Contrib. Nephrol. 170, 66-74 (2011
46. Thornalley, P. J. & Rabbani, N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin. Dial. 22, 400-404 (2009
47. De Vriese, A. S., Flyvbjerg, A., Mortier, S., Tilton, R. G. & Lameire, N. H. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J. Am. Soc. Nephrol. 14, 2109-2118 (2003
48. Shu, K. H. et al. Association of interleukin1β gene polymorphism and peritonitis in uremic patients undergoing peritoneal dialysis. Blood Purif. 32, 156-160 (2011
49. Uchiyama, K. et al. Impact of a genetic polymorphism of the interleukin1 receptor antagonist on technique survival in peritoneal dialysis patients. Blood Purif. 23, 450-458 (2005
50. Bellon, T. et al. Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis. Nephrol. Dial. Transplant. 26, 2995-3005 (2011
51. Hagg, D. A. et al. Expression of chemokine (CC motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis 204, e15-e20 (2009
52. Sampimon, D. E., Vlijm, A., Phoa, S. S., Krediet, R. T. & Struijk, D. G. Encapsulating peritoneal sclerosis in a peritoneal dialysis patient using biocompatible fluids only: is Alport syndrome a risk factor? Perit. Dial. Int. 30, 240-242 (2010
53. Nessim, S. J., Perl, J. & Bargman, J. M. The reninangiotensinaldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int. 78, 23-28 (2010
54. Noh, H. et al. Angiotensin II mediates high glucose-induced TGFβ1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit. Dial. Int. 25, 38-47 (2005
55. Kiribayashi, K. et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 67, 1126-1135 (2005
56. Nakamoto, H. et al. Role of the renin-Angiotensin system in the pathogenesis of peritoneal fibrosis. Perit. Dial. Int. 28 (Suppl. 3), S83-S87 (2008
57. Mizuiri, S. et al. Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGFβ1 and VEGF expression in rat peritoneal mesothelial cells. Am. J. Nephrol. 30, 295-302 (2009
58. Duman, S. et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit. Dial. Int. 21, 219-224 (2001
59. Kolesnyk, I., Struijk, D. G., Dekker, F. W. & Krediet, R. T. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Neth. J. Med. 68, 15-23 (2010
60. Jing, S., Kezhou, Y., Hong, Z., Qun, W. & Rong, W. Effect of renin-Angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton) 15, 27-32 (2010
61. Wontanatawatot, W., Eiam-Ong, S., Leelahavanichkul, A. & Kanjanabuch, T. An update on RAAS blockade and peritoneal membrane preservation: The ace of art. J. Med. Assoc. Thai. 94 (Suppl. 4), S175-S183 (2011
62. Lewis, R. V. & McDevitt, D. G. Adverse reactions and interactions with beta-Adrenoceptor blocking drugs. Med. Toxicol. 1, 343-361 (1986
63. Oules, R., Challah, S. & Brunner, F. P. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol. Dial. Transplant. 3, 66-69 (1988
64. Hendriks, P. M. et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit. Dial. Int. 17, 136-143 (1997
65. Stegmayr, B. G. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit. Dial. Int. 17, 541-545 (1997
66. Topley, N. et al. Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines. Kidney Int. 46, 900-909 (1994
67. Liu, H. et al. A selective cyclooxygenase2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol. Int. 31, 508-515 (2007
68. Douma, C. E., de Waart, D. R., Zemel, D., Struijk, D. G. & Krediet, R. T. Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CAPD. Nephrol. Dial. Transplant. 16, 803-808 (2001
69. Aroeira, L. S. et al. Cyclooxygenase2 mediates dialysate-induced alterations of the peritoneal membrane. J. Am. Soc. Nephrol. 20, 582-592 (2009
70. Fabbrini, P. et al. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol. Dial. Transplant. 24, 3669-3676 (2009
71. Polubinska, A. et al. Dialysis solution containing hyaluronan: Effect on peritoneal permeability and inflammation in rats. Kidney Int. 57, 1182-1189 (2000
72. Flessner, M. F. The role of extracellular matrix in transperitoneal transport of water and solutes. Perit. Dial. Int. 21 (Suppl. 3), S24-S29 (2001
73. Harenberg, J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med. Res. Rev. 18, 1-20 (1998
74. De Vriese, A. S., Mortier, S. & Lameire, N. H. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis. Perit. Dial. Int. 21 (Suppl. 3), S354-S356 (2001
75. Margetts, P. Heparin and the peritoneal membrane. Perit. Dial. Int. 29, 16-19 (2009
76. Gambaro, G. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N. A. S. randomized trial. J. Am. Soc. Nephrol. 13, 1615-1625 (2002
77. Pletinck, A. et al. Oral supplementation with sulodexide inhibits neo-Angiogenesis in a rat model of peritoneal perfusion. Nephrol. Dial. Transplant. 27, 548-556 (2012
78. Fracasso, A. et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit. Dial. Int. 23, 595-599 (2003
79. Horiuchi, T. et al. Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: The role of hyaluronan synthesis. Kidney Int. 64, 2280-2290 (2003
80. Sitter, T., Sauter, M. & Haslinger, B. Modulation of fibrinolytic system components in mesothelial cells by hyaluronan. Perit. Dial. Int. 23, 222-227 (2003
81. Szeto, C. C. et al. Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis. 36, 609-614 (2000
82. Wang, T. et al. Hyaluronan decreases peritoneal fluid absorption: Effect of molecular weight and concentration of hyaluronan. Kidney Int. 55, 667-673 (1999
83. Wang, T. et al. Hyaluronan prevents the decreased net ultrafiltration caused by increased peritoneal dialysate fill volume. Kidney Int. 53, 496-502 (1998
84. Wang, T. et al. Intraperitoneal addition of hyaluronan improves peritoneal dialysis efficiency. Perit. Dial. Int. 19 (Suppl. 2), S106-S111 (1999
85. Moberly, J. B. et al. Effects of intraperitoneal hyaluronan on peritoneal fluid and solute transport in peritoneal dialysis patients. Perit. Dial. Int. 23, 63-73 (2003
86. Rosengren, B. I., Carlsson, O. & Rippe, B. Hyaluronan and peritoneal ultrafiltration: A test of the "filter-cake" hypothesis. Am. J. Kidney Dis. 37, 1277-1285 (2001
87. Wang, T. et al. Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis. J. Am. Soc. Nephrol. 8, 1915-1920 (1997
88. Kihm, L. P. et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J. Am. Soc. Nephrol. 22, 914-926 (2011
89. Flessner, M. F. et al. Peritoneal changes after exposure to sterile solutions by catheter. J. Am. Soc. Nephrol. 18, 2294-2302 (2007
90. Peters, T. et al. Mouse model of foreign body reaction that alters the submesothelium and transperitoneal transport. Am. J. Physiol. Renal Physiol. 300, F283-F289 (2011).